Clinical Trial

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-06-07.
Status change: Not Yet Recruiting → Recruiting 2024-05-20
Trial Details
NCT Number NCT05906992
Lead Sponsor Celltrion
Conditions Relapsing-remitting Multiple Sclerosis
Enrollment 512 participants
Start Date 2024-01-11
Primary Completion 2027-02 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2024-05-22